Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Sana Biotechnology, Inc. has announced a public offering of $75 million in common stock and pre-funded warrants, with an additional option for underwriters to purchase up to $11.25 million more [1][2]. Group 1: Offering Details - The public offering consists of $75 million in shares of common stock and pre-funded warrants for certain investors [1]. - The underwriters will have a 30-day option to purchase an additional $11.25 million in shares [1]. - All shares and warrants will be sold by Sana, and the offering is subject to market conditions [1]. Group 2: Underwriters - Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the offering [2]. Group 3: Regulatory Information - The offering is made under a Registration Statement on Form S-3, which has been declared effective by the SEC [3]. - A preliminary prospectus supplement will be filed to describe the terms of the offering, available through the SEC's website [3]. Group 4: Company Overview - Sana Biotechnology focuses on creating engineered cells as medicines for patients, with operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA [5].